91 results about "High plasma" patented technology

Method for etching organic low-k dielectric using ammonia, NH3, as an active etchant. Processes using ammonia results in at least double the etch rate of organic low-k dielectric materials than processes using N2 / H2 chemistries, at similar process conditions. The difference is due to the much lower ionization potential of NH3 versus N2 in the process chemistry, which results in significantly higher plasma densities and etchant concentrations at similar process conditions.

A method and apparatus for cleaning a chemical vapor deposition chamber are provided. The chemical vapor deposition chamber includes an inlet that introduces reactive species into the chamber from a remote plasma source while bypassing a gas distribution assembly of the chamber and an inlet that introduces reactive species from a remote plasma source into the chamber via the gas distribution assembly.

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

The invention is embodied in a method of processing a semiconductor workpiece in a plasma reactor chamber, including supplying a polymer and etchant precursor gas containing at least carbon and fluorine into the chamber at a first flow rate sufficient of itself to maintain a gas pressure in the chamber in a low pressure range below about 20 mT, supplying a relatively non-reactive gas into the chamber at second flow rate sufficient about one half or more of the total gas flow rate into the chamber, in combination with the first flow rate of the precursor gas, to maintain the gas pressure in the chamber in a high pressure range above 20 mT, and applying plasma source power into the chamber to form a high ion density plasma having an ion density in excess of 1010 ions per cubic centimeter. In one application of the invention, the workpiece includes an oxygen-containing overlayer to be etched by the process and a non-oxygen-containing underlayer to be protected from etching, the precursor gas dissociating in the plasma into fluorine-containing etchant species which etch the oxygen-containing layer and carbon-containing polymer species which accumulate on the non-oxygen-containing underlayer. Alternatively, the high pressure range may be defined as a pressure at which the skin depth of the inductive field exceeds {fraction (1 / 10)} of the gap between the inductive antenna and the workpiece.

A method of vehicle modulated administration of an anticonvulsive agent to the nasal mucous membranes of humans and animals is disclosed. The vehicle system is an aqueous pharmaceutical carrier comprising an aliphatic alcohol, a glycol and a biological surfactant such as a bile salt or a lecithin. The pharmaceutical composition provides a means to control and promote the rate and extent of transmucosal permeation and absorption of the medicaments via a single and multiple administration. Nasal administration of the pharmaceutical preparation produces a high plasma concentration of the anticonvulsant nearly as fast as intravenous administration. Such compositions are particularly suitable for a prompt and timely medication of patients in the acute and / or emergency treatment of status epilepticus and other fever-induced seizures.

This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm2 and containing 0.1 to 3.15 mg / cm2 of rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which induces a mean plasma concentration of rotigotine in the range of 0.4 to 2 ng / ml 24 h after administration.

The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

Diazepam is administered intranasally in the form of specific microemulsions having advantageous properties. The microemulsions are comprised of about equal quantities of a fatty acid and water with the remainder being a hydrophilic surfactant, a polar solvent and an alcohol in a weight ratio such that alcohol is present in a greater quantity by weight than either of the other two. Nasal administration of the subject microemulsions produces a high plasma concentration of diazepam nearly as fast as intravenous administration. The present microemulsions are particularly suitable for a prompt and timely treatment of patients in the acute and / or emergency treatment of status epilepticus and other fever-induced seizures.

There are proposed a plasma treating apparatus and a plasma treating method using the same capable of improving the durability of site, member and parts in a chamber used for plasma etching in a corrosive gas atmosphere, which are exposed to the plasma atmosphere, and improving the resistance to plasma erosion of a coating formed on the surface of the member or the like in the corrosive gas atmosphere and preventing the occurrence of particles of a corrosion product even under a high plasma power. As a means therefore, in a plasma treating apparatus wherein a surface of a body to be treated in a chamber is subjected to a plasma treatment with an etching gas, at least surfaces of sites of the chamber itself exposing to the plasma atmosphere, or surfaces of a member or parts accommodated in the chamber are covered with a composite layer including a porous layer made from a metal oxide and a secondary recrystallized layer of the metal oxide formed on the porous layer.

The invention discloses an integral micro-discharge cold plasma cosmetic instrument mainly comprising an integrated case and a handheld electrode. According to the surface micro-discharge technology and the principle of dielectric barrier discharge, cold plasma is generated continuously stably, reaction with the chromophoric group is omitted, tissue vaporizing is not needed, separated skin is preserved completely and used as a natural dressing, and thus wound healing can be improved to facilitate recovery of patients. The integral micro-discharge cold plasma cosmetic instrument has the advantages of convenience in operation, high plasma generation efficiency, no gas supply device, and the like.

Method for etching organic low-k dielectric using ammonia, NH3, as an active etchant. Processes using ammonia results in at least double the etch rate of organic low-k dielectric materials than processes using N2 / H2 chemistries, at similar process conditions. The difference is due to the much lower ionization potential of NH3 versus N2 in the process chemistry, which results in significantly higher plasma densities and etchant concentrations at similar process conditions.

Provided is a plasma processing apparatus wherein durability of a part, a member and a component, which are exposed to plasma atmosphere in a chamber used for performing plasma etching in a corrosion resistant gas atmosphere is improved, resistance to plasma erosion of a film formed on the surface of the member and the like in the corrosion resistant gas atmosphere is improved, and furthermore, generation of particles of corrosion resistant products even under high plasma output is prevented. A plasma processing method using such plasma processing apparatus is also provided. In the plasma processing apparatus for processing the surface of a subject which is stored in the chamber to be processed is processed by etching process gas plasma. The part exposed to the plasma generating atmosphere in the chamber or the member arranged inside the chamber or the surface of the component is coated with at least a porous layer composed of a metal oxide and a secondary recrystallized layer of the metal oxide formed on the porous layer.

A novel method of vehicle modulated administration of an anticonvulsive agent to the mucous membranes of humans and animals is disclosed. The vehicle system is an aqueous pharmaceutical carrier comprising an aliphatic alcohol (10–80%) or a glycol (10–80%), and their combinations with a biological surfactant such as a bile salt or a lecithin. The pharmaceutical composition provides a means to control and promote the rate and extent of transmucosal permeation and absorption of the medicaments via a single and multiple administration. Nasal administration of the pharmaceutical preparation produces a high plasma concentration of the anticonvulsant nearly as fast as intravenous administration. Such compositions are particularly suitable for a prompt and timely medication of patients in the acute and / or emergency treatment of status epilepticus and other fever-induced seizures.

This invention aims at providing a plasma lipid composition selective adsorption separation porous membrane carrier materials, preparation methods and related applications. The porous membrane carrier used the average pore size of 0.05 m ~ 100 u medical nonwoven polymer as the starting raw materials, through a total of 60 Co-ray irradiation grafting copolymerization polyacrylic acid surface modification, it further fixed the cholesterol ligand by carboxyl of 1 - (3 - dimethyl amino-propyl ) -3 - ethyl activated carbon Diimide and biocompatibility ligand adsorption of heparin covalent coupling, finally get the polymer porous membrane carrier materials of plasma lipid selective adsorption separation ability. The invention related to the preparation method is simple, safe, effective and easy to promote large-scale production. With good material blood compatibility, it can be used as a plasma lipid composition adsorption separation of hyperlipidemia, dynamic perfusion of clinic high plasma patients' blood purification and waste blood separation renewable auxiliary materials.

The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

A member for a plasma etching device, which comprises a device substrate comprising quartz glass, aluminum, alumite or a combination thereof and, formed on the surface thereof, a coating film of yttrium oxide or YAG having a film thickness of 10 μm or more and a variation in the thickness of 10% or less, and preferably a surface roughness (Ra) of 1 μm or less; and a method for manufacturing the member for a plasma etching device, which comprises a step of plasma-spraying yttrium oxide or YAG to the surface of said device substrate or a step of fusing yttrium oxide or YAG with an oxyhydrogen flame, followed by coating the surface with the fused product, or a step of applying a solution containing yttrium, a yttrium compound or YAG on the above surface, followed by heating to fuse the resultant coating, or a combination of the above steps, thereby forming a coating film of yttrium oxide or YAG having a film thickness 10 μm or more and a variation in the thickness of 10% or less, and preferably a surface roughness (Ra) of 1 μm or less. The member for a plasma etching device is capable of retaining high plasma resistance for a long period of time, is free from the occurrence of the abnormal etching owing to partial change of electric characteristics, and thus can be used for a long time, in particular, even in the treatment of a large semiconductor device of a 12 inch silicon wafer.

The invention relates to a dasatinib liposome preparation, and a preparation method thereof. The dasatinib liposome preparation is high in biocompatibility; target modification can be carried out; sustained and controlled release of dasatinib can be realized; and it is beneficial for maintenance of relatively high plasma drug concentration in a long term, improvement of drug distribution, and increasing of drug bioavailability. The dasatinib liposome preparation possesses excellent lipophilic performance, is capable of passing through phospholipid bilayer in a molecular form and entering into inner water phase; pH value of liposome inner water phase is relatively low, the dasatinib moleculars are capable of bonding with hydrogen ions so as to form dasatinib ions, and combination with anions in an ammonium salt solution and forming of insoluble salts are realized, diffusion of dasatinib in the inner water phase into an outer water phase is inhibited, dasatinib is coated by the liposome inner water phase steadily, encapsulation efficiency and storage stability are improved, and excellent in-vitro slow release effect is achieved.

The long-term usage of AICR (5-aminio, 4-imidazole carboxamide riboside) to produce sustained metabolic and biological changes in mammals that overcome insulin resistance, i.e., increase insulin sensitivity, and result in benefits in diseases and conditions such as diabetes, hypertension, atherosclerosis, polycystic ovary syndrome and gallstones is described long-term usage of AICAR, particularly intermittent administration, e.g., three days per week, appears to have some of the positive effects of exercise, having an impact on the amount Of food consumed by a subject and resulting in reduced fat build-up and increase in muscle mass. Therefore, AICAR administration has a positive impact in reducing obesity. AICAR can also Prove useful in preventing or treating vascular diseases associated with hyperglycemia, high plasma levels of free fatty acids (FFA) and triglyceride, and insulin resistance by virtue of the fact that this agent activates fatty acid oxidation. Animal tests have Shown that chronic intermittent treatment with AICAR has not resulted in any noticeable toxic effects. AICAR and related compounds are activators of AMP-activated protein kinase (AMPK) and, furthermore, are effective at decreasing malonyl CoA levels in the animal.

The invention relates to a metformin hydrochloride sustained-release capsule and its preparation method. The metformin hydrochloride sustained-release capsule is prepared by steps of coating a metformin hydrochloride granule sustained-release material and putting into an enteric capsule. In comparison with the prior art, sustained-release granules and enteric capsule filling technology are combined together to prepare the new dosage form of metformin hydrochloride sustained-release (enteric-coated) capsule. As the sustained-release granule coating and enteric capsule filing technology is adopted, metformin hydrochloride will not be disintegrated and will not stimulates gastric mucosa, and adverse reactions such as nausea, stomachache, diarrhoea and the like caused by medication can be avoided. Meanwhile, metformin hydrochloride will not be damaged by gastric juice, and bioavailability of metformin hydrochloride is raised. In addition, the product provided by the invention is also a sustained-release enteric-coated preparation. The medicine can be stably released in a body, effective plasma concentration is maintained for a long time, and toxic and side effect which might be caused by higher plasma concentration within a short time are avoided. The frequency for taking the medicine is reduced, and patient compliance is also raised.

There are proposed a plasma treating apparatus and a plasma treating method using the same capable of improving the durability of site, member and parts in a chamber used for plasma etching in a corrosive gas atmosphere, which are exposed to the plasma atmosphere, and improving the resistance to plasma erosion of a coating formed on the surface of the member or the like in the corrosive gas atmosphere and preventing the occurrence of particles of a corrosion product even under a high plasma power. As a means therefore, in a plasma treating apparatus wherein a surface of a body to be treated in a chamber is subjected to a plasma treatment with an etching gas, at least surfaces of sites of the chamber itself exposing to the plasma atmosphere, or surfaces of a member or parts accommodated in the chamber are covered with a composite layer including a porous layer made from a metal oxide and a secondary recrystallized layer of the metal oxide formed on the porous layer.

Maintenance work on an apparatus is facilitated, the maintenance cycle is extended and an improvement in throughput is achieved. A processing chamber 2 and an auxiliary vacuum chamber 3 are connected via a transfer port 20 formed through their wall surfaces. At the inner wall of the transfer port 20, a detachable gate liner 100 constituted of a plurality of members is installed. The maintenance work at the inner wall of the transfer port is facilitated since the gate liner 100 alone simply needs to be disengaged to be washed, replaced or the like. Insulating films 200 and 300 constituted of a rare earth oxide spray-deposit film with high plasma erosion resistance are used to coat the surface of the gate liner 100 and the surface of a gate valve 4 over the area covering the transfer port 20. As a result, damage attributable to plasma does not occur readily at these surfaces, and the extent of metal contamination and dust generation is lowered.

The invention belongs to the field of medical beauty microneedles and particularly relates to a blank pipe fibroin microneedle drug administration system and a preparation method thereof. The blank pipe fibroin microneedle drug administration system comprises a microneedle casing, a medicine, a swelling interlayer, a coating, a pressure-sensitive adhesive coating and a backing layer. The surface of the microneedle casing is provided with a plurality of evenly arranged needle-shaped protrusions, needle-shaped cavities are positioned in the needle-shaped protrusions, the volume of the needle-shaped protrusions accounts for 40-90% that of the needle-shaped protrusions, tips of the needle-shaped protrusions are provided with through holes, and the diameters of the through holes are 10-50 [mu]m. Medicines are placed in the needle-shaped cavities. The microneedle drug administration system is simple and short in manufacturing process, mild in processing condition, simple in finished product structure, flexible in medicine loading mode, higher in drug loading rate, suitable for symptoms needing quick drug release and high plasma concentration and suitable for large-scale production.

The invention discloses an efficient florfenicol powder composition and a preparation method thereof. The powder composition comprises the following components in percentage by weight: 1-50% of florfenicol, 46-98.9% of a florfenicol-absorbed carrier and 0.05-4% of a florfenicol absorption promoter. The method comprises the following steps of: preparing the raw materials according to the above components; preparing a florfenicol organic solvent solution; dissolving the florfenicol absorption promoter and the florfenicol-absorbed carrier into water to obtain a mixed water solution; and adding the florfenicol organic solvent solution into the mixed water solution, and rapidly spray-drying. The preparation method disclosed by the invention is simple and low in cost. The product disclosed by the invention has the advantages of extrinsic quick release, esoteric quick absorption, high plasma peak concentration, thorough drug absorption and less antibiotic residue. The product disclosed by the invention can be applied to the treatment of infection on all parts of domestic animals caused by bacteria.

A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.

The invention discloses a stable high-restraint high-frequency small-amplitude boundary local die operation method suitable for a fusion reactor. On the condition of optimized high inner resistance, high boundary safety factor, high polarized specific voltage and high triangulation, high plasma energy storage and high plasma core restraint are obtained, and small-amplitude high-frequency boundary local die is obtained. The high core restraint facilitates sustaining of high parameter of the plasma core part and facilitates realization of a fusion reaction. A high-frequency small-amplitude boundary local die facilitates settlement of a first wall transient heat load problem, and furthermore has relatively high particle eliminating capability, thereby preventing a plasma impurity core polymerization problem. The operation parameter interval which is required by the method is compatible with the operation interval of a future fusion reactor. Furthermore stable state operation of the plasma can be realized. The stable high-restraint high-frequency small-amplitude boundary local die operation method has low breakage risk, excellent robustness and high repeatability. The stable high-restraint high-frequency small-amplitude boundary local die operation method has a relatively ideal operation mode which may be used for the reactor grade.

The invention provides a plasma processing method and plasma processing device for manufacturing semiconductor devices in which the number of foreign particles being adhered to the wafer is reduced greatly and the yield is improved. In a plasma processing device having a plasma source capable of controlling plasma distribution, the shape of a sheath / bulk boundary above the wafer is controlled to a convexed shape when the plasma is turned on and off. By adding a step of applying a low source power and wafer bias power when the plasma is turned on and off in order to realize an out-high plasma distribution, it is possible to form a sheath that is thicker near the center of the wafer and thinner at the outer circumference portion thereof.

A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and / or at a sufficient rate to enable desire effect. AKG, AKG derivatives or metabolites, AKG analogues or mixture thereof. Also conteplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixture thereof, for decreasing glucose adsorption as well as compositions for use in treatment.

High-deposition rate methods for forming transparent ashable hardmasks (AHMs) that have high plasma etch selectivity to underlying layers are provided. The methods involve placing a wafer on a powered electrode such as a powered pedestal for plasma-enhanced deposition. According to various embodiments, the deposition is run at low hydrocarbon precursor partial pressures and / or low process temperatures. Also provided are ceramic wafer pedestals with multiple electrode planes embedded with the pedestal are provided. According to various embodiments, the pedestals have multiple RF mesh electrode planes that are connected together such that all the electrode planes are at the same potential.

A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and / or at a sufficient rate to enable desire effect. AKG, AKG derivatives or metabolites, AKG analogues or mixture thereof. Also conteplated is a method for decreasing adsorption of glucose in a vertebrate, including mammal and bird, in the need thereof, AKG, AKG derivates or metabolites, AKG analogues or mixture thereof, for decreasing glucose adsorption as well as compositions for use in treatment.